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ABSTRACT 
Renal osteodystrophy (ROD) is a heterogeneous group of metabolic bone diseases that 
accompanies progressive chronic kidney disease (CKD). Bone biomarkers and bone imaging 
techniques may help to assess bone health and predict fractures in CKD, but do have 
important inherent limitations. A bone biopsy, performed after tetracycline labeling allows 
the proper assessment of the material and structural characteristics that contribute to bone 
quality and hence to bone strength. As confirmed by a recent survey among European 
nephrologists, bone biopsies are performed rather exceptionally, both for clinical and 
research purposes. Clinical research in the field of ROD is threatened by vanishing clinical 
and pathological expertise, small patient cohorts, and scientific isolation.  The EUropean 
Renal OsteoDystrophy (EUROD) initiative was recently created under the umbrella of the 
ERA-EDTA CKD-MBD working group to revitalize bone biopsy as a clinical useful tool in the 
diagnostic workup of CKD-MBD and to foster research on the epidemiology, implications and 
reversibility of ROD. As such, the EUROD initiative aims to increase the understanding of 
ROD and ultimately to improve outcomes in CKD patients. 
INTRODUCTION 
Renal osteodystrophy (ROD) is a heterogeneous group of metabolic bone diseases that 
accompanies progressive chronic kidney disease (CKD). These metabolic bone diseases have 
specifically defined quantitative histomorphometric diagnostic criteria as well as clinical 
features
1
. More recently, the Kidney Disease Improving Global Outcomes working group 
offered a new and more encompassing definition of renal bone disease, i.e. CKD-mineral and 
 
 
bone disorder (CKD-MBD)
2
. This more general definition recognizes that the pathophysiology 
of renal bone disease extends beyond the skeleton and that there are links between 
abnormal bone remodeling activity and the risk for soft tissue and vascular calcification 
(commonly referred to as the bone-vascular axis). In this new construct, the term ROD is 
limited to the specific changes in bone histology seen in CKD. Besides playing a crucial role in 
locomotion, the skeleton is increasingly recognized as an endocrine organ capable of 
producing various hormones involved in energy, glucose and mineral metabolism
3
. The bone 
thus may not only be a target but also a driver of mineral disturbances in CKD.   
Clinical research in the field of ROD lags behind and is threatened by vanishing clinical and 
pathological expertise in bone biopsy retrieval and reading, small patient cohorts, and 
scientific isolation.  ROD, however, is not innocent as it may result in fractures, bone pain, 
deformities in growing children, reduced growth velocity, and abnormal height and indirectly 
to vascular calcification and increased (cardiovascular) mortality
1;4
. Bone biomarkers
5
 and 
bone imaging techniques (DXA, MRI, hr-pQCT, 18F-fluoride positron emission tomography  ? ?
may help to assess bone health and predict fractures in CKD, but do have important inherent 
limitations. A bone biopsy, performed after tetracycline labeling allows the proper 
assessment of the material and structural characteristics that contribute to bone quality and 
hence to bone strength
6
. 
Patients with CKD are at increased risk of fractures. The fracture risk steadily increases 
along the progression of renal disease to become 4 times higher in end stage renal disease 
patients than in non-renal counterparts
7 ? The risk further increases, at least transiently, 
following renal transplantation
8
.   Compared with those without fractures, patients with 
CKD experience a multifold increased risk of mortality
9
. 
 
The challenge for physicians managing fragility fractures in patients with CKD is 
discriminating fractures due to senile osteoporosis from fractures due to ROD
10
. Both a 
high fall risk
11
and an impaired bone strength account for the increased fracture risk in 
CKD.  Bone strength is determined by bone quantity and bone quality. Several lines of 
evidence indicate that CKD is a state of low bone mass and accelerated bone loss
12
 Bone 
mass can be evaluated non-invasively by imaging techniques such as DXA and pQCT. It is 
increasingly acknowledged that, similar to the general population, low BMD predicts 
fracture risk in CKD. Since adjustment for BMD does not nullify the association between 
CKD and increased fracture risk, CKD may be equally considered a state of impaired bone 
quality. Bone turnover, mineralization, microarchitecture, microfractures and matrix and 
mineral composition are all important determinants of bone quality. A bone biopsy 
remains at present a prerequisite for proper evaluation of bone quality. Non-invasive 
analytical approaches, such as biomarkers and isotope and imaging techniques are 
developed. It is however unlikely that these techniques will render bone biopsies obsolete 
in the work-up of low impact fractures or unexplained bone pain in the setting of 
advanced CKD. These techniques will complement rather than replace bone biopsy as a 
diagnostic tool. 
Here, we present the results of a pan-European survey on the use of bone biopsies in the 
management or ROD. We also propose the formation of a European network to facilitate 
research and improve management of ROD. 
 
BONE BIOPSY PRACTICE PATTERN: A EUROPEAN SURVEY  
Despite being considered the gold standard in diagnosing renal bone disease, bone biopsies 
are performed rather exceptionally in daily clinical practice. To get a better insight in current 
bone biopsy practice patterns and attitudes towards the procedure across Europe, an 
electronic survey was sent out in May 2015 to all European members of the ERA-EDTA CKD-
MBD working group (n=230), complemented by European opinion leaders (n=13). Seventy-
eight invitees completed the survey, corresponding to a response rate of  32 %. All regions of 
Europe were represented. The main activity of the respondents was clinical nephrology 
(50%), followed by dialysis (26%), transplantation (9%) and research (9%). The majority of 
respondents (89%) work in tertiary academic referral hospitals. The following paragraphs 
summarize the main results of the survey.  
Current practice patterns:  Half of the respondents reported to have performed bone 
biopsies in the past 5 years; among them, 27.2% have performed bone biopsies for research 
purposes only. Most respondents thus perform bone biopsies for clinical purposes. The total 
number of procedures per respondent over the last 5 years was low, being less than 10. In 
58.9 % of the cases, nephrologists were in charge of the bone biopsy procedure. In other 
centers, bone biopsies were performed by surgeons (12.5%) or rheumatologists (5.4%). The 
(trans)iliac horizontal approach was most commonly used (65.5%), followed by the vertical 
approach (29.1%). Only few (8.0%) performed drill-assisted bone biopsies. Small (inner 
diameter < 5mm) and non-disposable trephine needles are gaining popularity (almost 40% 
penetrance) at the expense of the large, non-disposable Bordier and Bedford trephine 
needles. Most procedures (66.7%) were performed with local anaesthesia in combination 
with light sedation (midazolam). Histomorphometry was mostly performed in external 
laboratories.  
Indications: Most respondents agreed on the following bone biopsy indications: low impact 
fracture, unexplained bone pain, prior to parathyroidectomy (to confirm high bone turnover) 
or initiation of antiresorptive drugs (to exclude low bone turnover), unexplained 
hypercalcemia or radiologic abnormality, and suspected or proven overload or toxicity to 
heavy or rare metal. Also, a discordance between PTH and alkaline phosphatase level is 
considered an indication for a bone biopsy by almost 50% of the respondents.  Most 
respondents consider a stand-alone PTH level outside the KDIGO target range insufficient to 
proceed with a bone biopsy. While a majority of respondents consider a PTX valuable to 
confirm high bone turnover before parathyroidectomy, they mostly disagree with the 
statement that a bone biopsy should be performed before initiating PTH suppressive therapy 
(calcimimetics, active vitamin D analogs) (figure 1). 
Limitations/hurdles: Multiple hurdles hampering the widespread implementation of bone 
biopsies were identified. These included laborious sampling procedure, time consuming and 
costly histopathological analysis, and missing histopathological expertise. Fifty-one percent 
of the respondents state that procedural pain is a hurdle to the widespread implementation 
of bone biopsy as a diagnostic clinical tool (figure 2).  
In aggregate, the results of this survey teach us that a bone biopsy overall is perceived as an 
invasive, painful, laborious procedure and that histomorphometric expertise is not widely 
available. Histomorphometry moreover is complex, time-consuming  and costly, all 
important hurdles in an era in which cost savings and immediate feedback are increasingly 
appreciated. Consequently, bone biopsies at present are nowhere part of routine 
assessment and follow-up and are performed in specific cases in a limited number of centers 
only. A negative spiral is ongoing, which finally risks to result in the complete disappearance 
of the expertise.  
  
THE EUROD INITIATIVE 
In an attempt to halt this negative spiral the EUropean Renal OsteoDystrophy (EUROD) 
initiative was created under the umbrella of the ERA-EDTA CKD-MBD working group. 
hZK ?ƐƉƌŝŵĂƌǇŵŝƐƐŝŽŶŝƐƚŽƌĞǀŝƚĂůŝǌĞďŽŶĞďŝŽƉƐǇĂƐĂĐůŝŶŝĐĂůƵƐĞĨƵůƚŽŽůŝŶƚŚĞĚŝĂŐŶŽƐƚŝĐ
workup of CKD-MBD and to facilitate research on the epidemiology, implications and 
reversibility of ROD.  
A bone biopsy is deemed an interesting scientific tool
13
, but only seldom considered in daily 
clinical practice. A bone biopsy has a negative connotation, which may be dated as less 
invasive and demanding approaches have become available. Especially the reduced 
procedural complexity and morbidity related to the use of smaller and disposable trephine 
needles may lower the threshold for performing a bone biopsy. There is almost no tradeoff 
as most procedures with these needles yield sufficient bone tissue for bone 
histomorphometry. Even more threatening for the survival of bone biopsy as a diagnostic 
procedure is the vanishing reservoir of experts in clinical histomorphometry. Both a low 
clinical demand and budgetary restrictions erased step by step interest in clinical 
histomorphometry.   
Today, epidemiological  studies on the pattern of ROD across stages of CKD are sparse and 
often flawed by selection bias. Published data may not be valid, given that a considerable 
proportion of biopsies were retrieved during research projects. Also, regional differences in 
ethnic background, demographics and CKD-MBD treatment may limit the applicability of 
global collaborative reports for local health care practitioners. A European collaboration of 
clinicians, specialized on treating bone disorders in CKD and on retrieving bone biopsies in 
clinical settings, could result in more valid epidemiologic data and serve as a forum for 
interventional studies involving bone biopsies. 
Studies investigating the association between indices of bone quality and prevalent and 
incident fractures are limited. An overarching cohort study, combing bone biopsy databases 
from different European centers, would offer a blueprint of contemporaneous renal bone 
disease in Europe and may offer hints to biological factors and mechanisms underlying the 
increased fracture risk in CKD.  
The armamentarium to tackle senile osteoporosis is rapidly expanding
10
. Clinical trials of 
senile osteoporosis therapy generally excluded patients with advanced kidney disease. This 
leaves nephrologists with ignorance with regard to role, efficacy and safety of established 
and novel agents for the treatment of osteoporosis in these patients and paves the way for 
therapeutic nihilism. Post-hoc analyses of large studies in postmenopausal women showed a 
similar benefit in CKD patients without biochemical abnormalities suggesting CKD-MBD as in 
the general population. Additional studies are urgently required to evaluate the impact of 
antiresorptive and anabolic agents on bone health and fracture risk in CKD patients. A 
European collaborative effort offers the best soil for initiating and successfully completing 
such intervention studies.  
After kidney transplantation, bone disorders often persist due to incomplete recovery of 
pre-existing disturbances of mineral metabolism, de-novo CKD-MBD due to reduced kidney 
graft function, and the negative effect of immunosuppression on bone
14
. However, little is 
known about the association of laboratory abnormalities with bone disorders, vascular 
pathology, and outcome after kidney transplantation. The few and small bone biopsy studies 
that have been performed suggest a dissociation of circulating bone turnover markers and 
bone histomorphometric findings and an increasing prevalence of low bone turnover with 
time from transplantation 
15-18
. The EUROD initiative will facilitate further exploration of the 
pathophysiology of post-transplant CKD-MBD and enable the performance of interventional 
studies aimed at treatment and prevention of bone- and vascular complications. 
The aims of the EUROD initiative include the following: 
1. To revitalize bone biopsy as a clinically useful tool in daily practice. Bone biopsies 
should regain a prominent place in daily practice to help tailoring CKD-MBD therapy 
for the individual patient, a relevant goal in era favoring personalized medicine. We 
envisage the following initiatives to achieve this aim: 
a. Organize hands on workshops for clinicians and pathologists spreading 
expertise in the field 
b. Harmonize the bone biopsy procedure, sample handling and reading 
(standard operating procedures, SOP). Publish SOP, both with regard to the 
bone biopsy procedure, analysis and report. 
c. Define normal ranges for static and dynamic histomorphometric parameters 
d. Report on the pattern of ROD in contemporaneous European CKD patients 
2. To promote and organize pan-European research in the field or ROD. We foresee the 
following initiatives to achieve this aim: 
a. Create an online repository of existing European clinical material and network 
of investigators in the field of renal osteodystrophy 
b. Identify research networks and research questions that can be addressed by 
pooling existing data, once the repository is created. These questions may 
relate to the epidemiology, implications and reversibility/treatment of ROD. 
c. Develop standard operating procedures (SOP) for diagnosis, including the 
bone biopsy procedure, analysis and report (see above), bone biomarkers and 
imaging techniques. 
d. Search for a less demanding but equally relevant and accurate analytical 
alternative to classical histomorphometry for the diagnosis of ROD. Classical 
 ‘ŽƉĞƌĂƚŽƌ ĚĞƉĞŶĚŝŶŐ ? ŚŝƐƚŽŵŽƌƉŚŽŵĞƚƌǇ ŝƐ ǀĞƌǇ ůĂďŽƌŝƵƐ ĂŶĚ ƚŝŵĞ-
ĐŽŶƐƵŵŝŶŐ ? ĐƵƌƚĂŝůŝŶŐ  ‘ƌŽƵƚŝŶĞ ? ĂŶĂůǇƐŝƐ ? Bone biomarkers 19, isotope 20 and 
imaging (MRI, HR-pQCT, 18F-ĨůƵŽƌŝĚĞ ƉŽƐŝƚƌŽŶ ĞŵŝƐƐŝŽŶ ƚŽŵŽŐƌĂƉŚǇ ?) 
techniques, though promising non-invasive alternatives for bone biopsy, so 
far did not fulfill expectations in CKD. Additional validation studies in larger 
cohorts with simultaneous data on bone histomorphometry across the 
spectrum of CKD are mandatory. 
e. To initiate and support clinical intervention studies aimed at ameliorating 
ROD and fracture risk 
3. To improve and distribute knowledge in the field of ROD. We envisage the following 
initiatives to achieve this aim 
a. Collaborate with the European Best Practice Guideline group in the updating 
process of guidelines related to the care of ROD. 
b. Collaborate with ERA-EDTA registry and EURODOPPS initiative to evaluate 
current practice patterns with regard to evaluation of ROD. 
c. To collaborate on educational activities around ROD within the ERA-EDTA 
(CKD-MBD working group) including a) the organization of an annual working 
group meeting; b) preparation of position papers and review articles on 
relevant ROD issues; c)the organization of symposia (including work-shops) 
specifically dedicated to ROD. 
4. To closely collaborate and interact with similar initiatives elsewhere in the world, e.g. 
REBRABO
21
. 
5. To closely collaborate with other bone and mineral societies across the world 
 
CONCLUSION 
It is time to halt the negative spiral of bone biopsy procedures. A bone biopsy often remains 
indispensable in the work-up of low-impact fracture in the setting of advanced CKD. Low-
impact fractures are common among CKD patients. Their prevention and treatment is 
challenging and at the same time frustrating, because the lack of evidence. A more 
widespread implementation of bone biopsies as diagnostic procedure may widen the 
therapeutic horizon and may foster the development and validation of non-invasive 
alternatives. 
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FIGURE LEGENDS 
 
Figure 1.: ZĞƐƉŽŶƐĞƐƚŽƋƵĞƐƚŝŽŶ P “WůĞĂƐĞŝŶĚŝĐĂƚĞǁŚĞƚŚĞƌǇŽƵĂŐƌĞĞŽƌŶŽƚĨŽůůŽǁŝŶŐ
ƉŽƚĞŶƚŝĂůŝŶĚŝĐĂƚŝŽŶƐƚŽƉĞƌĨŽƌŵĂďŽŶĞďŝŽƉƐǇ ? ?Percentage distribution: grey: neutral; light 
green: agree; dark green: strongly agree; orange: disagree; red: strongly disagree. 
Figure 2 PZĞƐƉŽŶƐĞƐƚŽƋƵĞƐƚŝŽŶ P “tŚĂƚĂƌĞŝŶǇŽƵƌŽƉŝŶŝŽŶŚƵƌĚůĞƐƚŽĂŵŽƌĞǁŝĚĞƐƉƌĞĂĚ
ĐůŝŶŝĐĂůŝŵƉůĞŵĞŶƚĂƚŝŽŶŽĨďŽŶĞďŝŽƉƐŝĞƐŝŶ<ƉĂƚŝĞŶƚƐ ? ? ?Percentage distribution: grey: 
neutral; light green: agree; dark green: strongly agree; orange: disagree; red: strongly 
disagree.  
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